权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Participant Recruitment, Enrollment and Characterization Core

参与者招募、登记和表征核心

基本信息

批准号：
8077360
负责人：
CHARLES DRESCHER
金额：
$ 26.43万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8077360
关键词：
Academic Medical Centers Advisory Committees Advocate Arts Biostatistics Core Blood California Cancer Patient Cancer Research Project Caring Cities Clinical Clinical Data Clinical Investigator Clinical Trials Collaborations Committee Members Communities Community Physician Consent Development Diagnosis Discipline of obstetrics Enrollment Ensure Epidemiology Funding Goals Gynecology Health Personnel High Risk Woman Image Informatics Instruction Internal Medicine Leadership Life Los Angeles Malignant neoplasm of ovary Medical Medical Oncology Neoadjuvant Therapy Operative Surgical Procedures Ovarian Participant Patient Care Patient Recruitments Patients Phase Phase I Clinical Trials Physicians Pilot Projects Primary Health Care Procedures Protocols documentation Provider Recruitment Activity Recurrence Reporting Reproduction spores Research Research Activity Research Personnel Research Subjects Risk Screening for Ovarian Cancer Screening procedure Serum Markers Site Specimen Symptoms Testing Time Translating Translational Research Washington Woman Work anticancer research base cohort design efficacy trial experience falls follow-up medical specialties meetings member novel patient advocacy group prevent programs research study success tumor

项目摘要

Clinical interaction with patients and health care providers is crucial to the success ofthe research studies proposed within the SPORE and to the long-term success of translational ovarian cancer research. The Patient Recruitment, Enrollment and Characterization Core (referred to in this document as the Clinical Core) provides the clinical expertise and the physician and patient interaction which is necessary for the successful completion of the research objectives of the SPORE projects and pilot activities. The POCRC Clinical Core has demonstrated a strong track-record in recruiting large cohorts of women at risk for developing ovarian cancer (pre-diagnosis cohort) and women with ovarian cancer at the time of diagnosis (incident cases cohort) and during treatment and follow-up (post diagnosis cohort). Using uniform protocols to approach, consent, enroll, and track participants, over 3400 women have been enrolled into POCRC SPORE (n=1740) inter-SPORE (n=1112) and investigator initiated ROI funded (n= 637) ovarian cancer research projects. As in prior years, continued success ofthe Pacific Ovarian Cancer Research Consortium depends on the recruitment of participants into research studies including clinical trials. Building on our prior success and experience, the POCRC Clinical Core will refine participant contact and enrollment procedures to support all ofthe projects in this SPORE application as well as developmental research activities and collaborations within and outside ofthe SPORE. Working in concert-with the Clinical Specimen Management and Characterization Core and the Biostatistics and Informatics Core, the clinical core will identify participants for clinical trials and provide bio-specimens and associated clinical data that are necessary to meet the research objectives ofthe SPORE. The activities of the Clinical Core are expanding to include sites at Stanford University Medical Center, Palo Alto, California and City of Hope, Duarte, California. The addition of these sites is consistent with our goal of uniting major ovarian cancer research centers along the West Coast. RELEVANCE (See instructions): The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase 1 trial results with reports from ongoing Phase 111 efficacy trials; 2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature; and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.

与患者和医疗保健提供者的临床互动对研究的成功至关重要